Close Menu

NEW YORK – Qiagen said after the close of the market on Monday that it is collaborating with Amgen to develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer (NSCLC).

The Therascreen CDx test will use real-time PCR to identify patients with cancers that have the KRAS G12C mutation, one of the most common causes of cancer. The RAS gene family includes the most frequently mutated oncogenes in cancers with KRAS being the most prevalent driver in NSCLC.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.